Literature DB >> 21692504

A substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors.

Anna Mari Lone1, Daniel A Bachovchin, David B Westwood, Anna E Speers, Timothy P Spicer, Virneliz Fernandez-Vega, Peter Chase, Peter S Hodder, Hugh Rosen, Benjamin F Cravatt, Alan Saghatelian.   

Abstract

Peptidases play vital roles in physiology through the biosynthesis, degradation, and regulation of peptides. Prolyl endopeptidase-like (PREPL) is a newly described member of the prolyl peptidase family, with significant homology to mammalian prolyl endopeptidase and the bacterial peptidase oligopeptidase B. The biochemistry and biology of PREPL are of fundamental interest due to this enzyme's homology to the biomedically important prolyl peptidases and its localization in the central nervous system. Furthermore, genetic studies of patients suffering from hypotonia-cystinuria syndrome (HCS) have revealed a deletion of a portion of the genome that includes the PREPL gene. HCS symptoms thought to be caused by lack of PREPL include neuromuscular and mild cognitive deficits. A number of complementary approaches, ranging from biochemistry to genetics, will be required to understand the biochemical, cellular, physiological, and pathological mechanisms regulated by PREPL. We are particularly interested in investigating physiological substrates and pathways controlled by PREPL. Here, we use a fluorescence polarization activity-based protein profiling (fluopol-ABPP) assay to discover selective small-molecule inhibitors of PREPL. Fluopol-ABPP is a substrate-free approach that is ideally suited for studying serine hydrolases for which no substrates are known, such as PREPL. After screening over 300,000 compounds using fluopol-ABPP, we employed a number of secondary assays to confirm assay hits and characterize a group of 3-oxo-1-phenyl-2,3,5,6,7,8-hexahydroisoquinoline-4-carbonitrile and 1-alkyl-3-oxo-3,5,6,7-tetrahydro-2H-cyclopenta[c]pyridine-4-carbonitrile PREPL inhibitors that are able to block PREPL activity in cells. Moreover, when administered to mice, 1-isobutyl-3-oxo-3,5,6,7-tetrahydro-2H-cyclopenta[c]pyridine-4-carbonitrile distributes to the brain, indicating that it may be useful for in vivo studies. The application of fluopol-ABPP has led to the first reported PREPL inhibitors, and these inhibitors will be of great value in studying the biochemistry of PREPL and in eventually understanding the link between PREPL and HCS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692504      PMCID: PMC3145007          DOI: 10.1021/ja2036095

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  45 in total

1.  Profiling enzyme activities in vivo using click chemistry methods.

Authors:  Anna E Speers; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2004-04

Review 2.  Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.

Authors:  Ann E Weber
Journal:  J Med Chem       Date:  2004-08-12       Impact factor: 7.446

3.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

Authors:  D Marguet; L Baggio; T Kobayashi; A M Bernard; M Pierres; P F Nielsen; U Ribel; T Watanabe; D J Drucker; N Wagtmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 4.  Serine proteases: structure and mechanism of catalysis.

Authors:  J Kraut
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

5.  PREPL, a prolyl endopeptidase-like enzyme by name only?--Lessons from patients.

Authors:  Kurt Boonen; Luc Régal; Jaak Jaeken; John W M Creemers
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-05       Impact factor: 4.388

Review 6.  Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.

Authors:  Jonathan S Rosenblum; John W Kozarich
Journal:  Curr Opin Chem Biol       Date:  2003-08       Impact factor: 8.822

7.  Glucagon-like peptide-1 7-36: a physiological incretin in man.

Authors:  B Kreymann; G Williams; M A Ghatei; S R Bloom
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

8.  Post-proline cleaving enzyme. Synthesis of a new fluorogenic substrate and distribution of the endopeptidase in rat tissues and body fluids of man.

Authors:  T Yoshimoto; K Ogita; R Walter; M Koida; D Tsuru
Journal:  Biochim Biophys Acta       Date:  1979-08-15

9.  Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.

Authors:  Maria A Cavasin; Nour-Eddine Rhaleb; Xiao-Ping Yang; Oscar A Carretero
Journal:  Hypertension       Date:  2004-03-22       Impact factor: 10.190

10.  1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

Authors:  Edwin B Villhauer; John A Brinkman; Goli B Naderi; Bryan F Burkey; Beth E Dunning; Kapa Prasad; Bonnie L Mangold; Mary E Russell; Thomas E Hughes
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

View more
  12 in total

1.  Fluorescence polarization assays in high-throughput screening and drug discovery: a review.

Authors:  Matthew D Hall; Adam Yasgar; Tyler Peryea; John C Braisted; Ajit Jadhav; Anton Simeonov; Nathan P Coussens
Journal:  Methods Appl Fluoresc       Date:  2016-04-28       Impact factor: 3.009

2.  Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization.

Authors:  Myles B C Dillon; Daniel A Bachovchin; Steven J Brown; M G Finn; Hugh Rosen; Benjamin F Cravatt; Kerri A Mowen
Journal:  ACS Chem Biol       Date:  2012-04-20       Impact factor: 5.100

3.  N-Acyl pyrazoles: Effective and tunable inhibitors of serine hydrolases.

Authors:  Katerina Otrubova; Shreyosree Chatterjee; Srijana Ghimire; Benjamin F Cravatt; Dale L Boger
Journal:  Bioorg Med Chem       Date:  2019-03-11       Impact factor: 3.641

4.  Selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival.

Authors:  Jae Won Chang; Andrea M Zuhl; Anna E Speers; Sherry Niessen; Steven J Brown; Melinda M Mulvihill; Yi Chiao Fan; Timothy P Spicer; Mark Southern; Louis Scampavia; Virneliz Fernandez-Vega; Melissa M Dix; Michael D Cameron; Peter S Hodder; Hugh Rosen; Daniel K Nomura; Ohyun Kwon; Ku-Lung Hsu; Benjamin F Cravatt
Journal:  ACS Chem Biol       Date:  2015-01-20       Impact factor: 5.100

5.  Discovery libraries targeting the major enzyme classes: the serine hydrolases.

Authors:  Katerina Otrubova; Venkat Srinivasan; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2014-06-27       Impact factor: 2.823

6.  A new class of rhomboid protease inhibitors discovered by activity-based fluorescence polarization.

Authors:  Eliane V Wolf; Annett Zeißler; Oliver Vosyka; Evelyn Zeiler; Stephan Sieber; Steven H L Verhelst
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

7.  AIG1 and ADTRP are atypical integral membrane hydrolases that degrade bioactive FAHFAs.

Authors:  William H Parsons; Matthew J Kolar; Siddhesh S Kamat; Armand B Cognetta; Jonathan J Hulce; Enrique Saez; Barbara B Kahn; Alan Saghatelian; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2016-03-28       Impact factor: 15.040

Review 8.  Advanced Activity-Based Protein Profiling Application Strategies for Drug Development.

Authors:  Shan Wang; Yu Tian; Min Wang; Min Wang; Gui-Bo Sun; Xiao-Bo Sun
Journal:  Front Pharmacol       Date:  2018-04-09       Impact factor: 5.810

9.  PREPL deficiency: delineation of the phenotype and development of a functional blood assay.

Authors:  Luc Régal; Emma Mårtensson; Isabelle Maystadt; Nicol Voermans; Damien Lederer; Alberto Burlina; María Jesús Juan Fita; A Jeannette M Hoogeboom; Mia Olsson Engman; Tess Hollemans; Meyke Schouten; Sandra Meulemans; Tord Jonson; Inge François; David Gil Ortega; Erik-Jan Kamsteeg; John W M Creemers
Journal:  Genet Med       Date:  2017-07-20       Impact factor: 8.822

10.  Deletion of PREPl causes growth impairment and hypotonia in mice.

Authors:  Anna Mari Lone; Mathias Leidl; Amanda K McFedries; James W Horner; John Creemers; Alan Saghatelian
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.